Michigan Medicine Launches Multi-Site COVID-19 Clinical Trial on New HERO Registry

April 29, 2020

The University of Michigan has been selected to participate in the first study to use the new national Healthcare Worker Exposure Response & Outcomes (HERO) registry. Supported by the CTSO’s Ambulatory & Chronic Disease (ACD) Clinical Trials Support Unit (CTSU), in collaboration with Michigan Institute for Clinical & Health Research (MICHR), this study focuses on how effective Hydroxychloroquine (HCQ) may be in protecting healthcare providers. 

Led by Marisa Miceli, MD, Associate Professor, Infectious Diseases, Internal Medicine, and Peter Higgins, MD, PhD, MSc, Professor, Division of Gastroenterology; Director, IBD Program; and Medical Director, ACD CTSU, the study aims to determine if HCQ can prevent COVID infections or reduce the severity of COVID infections in providers.

“This provider prevention study, with 15,000 healthcare providers nationwide, randomizes health care providers to HCQ vs placebo,” said Peter Higgins, MD, PhD, MSc (CRDSA), “We intend to identify whether HCQ can reduce infections in healthcare providers at high risk and reduce the severity of COVID-19 infections.”

Marisa Miceli, MD, will be leading the collection of 1,000+ nasal swabs when she is doing clinical service, as part of the study. 

The HERO registry collects information from healthcare workers to better understand the impact that the COVID-19 pandemic has on them, their colleagues, family, and friends. The registry is open to all healthcare workers, including nurses, therapists, physicians, emergency responders, food service workers, environmental service workers, interpreters, and transporters.

Michigan Medicine healthcare workers who want to help others understand the impact COVID-19 can learn more and sign up here.